FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
3.22B
3.08B
3.34B
3.8B
4.13B
4.41B
4.7B
5.02B
5.35B
5.71B
212.7M
245M
369.7M
252.2M
256.3M
339.29M
361.95M
386.12M
411.91M
439.41M
-167.6M
-104.5M
-94M
-150.3M
-184.9M
-174.99M
-186.68M
-199.14M
-212.44M
-226.63M
45.1M
140.5M
275.7M
101.9M
71.4M
164.3M
175.27M
186.98M
199.46M
212.79M
5.59
5.59
5.59
5.59
5.59
155.6M
157.21M
158.83M
160.47M
162.12M
794.24M